Analysis of 3-year national reimbursement application data on etanercept and efalizumab for psoriasis.
Driessen
R J B
RJ
de Jong
E M G J
EM
de Rie
M A
MA
Salemink
G W
GW
van de Kerkhof
P C M
PC
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000191:economics*; D061067:Antibodies, Monoclonal, Humanized; D016527:Drug Costs; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics*; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D011565:Psoriasis / Q000188:drug therapy* / Q000191:economics*; D012051:Reimbursement Mechanisms / Q000706:statistics & numerical data*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; C472181:efalizumab